<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881101</url>
  </required_header>
  <id_info>
    <org_study_id>LPS- PH I -01-2009</org_study_id>
    <nct_id>NCT00881101</nct_id>
  </id_info>
  <brief_title>Clinical Study of Liposomal Paclitaxel in Chinese Patients</brief_title>
  <official_title>Dose Escalation Study of Liposomal Paclitaxel in Chinese Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Sike Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Sike Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose and dose limiting&#xD;
      toxicities of liposomal paclitaxel in Chinese patients with solid tumors in advanced stages.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are clinical trials show that paclitaxel is common option for the treatment of solid&#xD;
      tumors. Liposomal paclitaxel has different pharmacokinetic features comparing with&#xD;
      conventional paclitaxel. However,the tolerance of this new dosage form of paclitaxel&#xD;
      (liposomal paclitaxel) has never been studied in Chinese cancer patients. This study is&#xD;
      designed to find the maximum tolerated dose and dose limiting toxicities of liposomal&#xD;
      paclitaxel in Chinese cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>dose limiting toxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal paclitaxel</intervention_name>
    <description>All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: from 18 to 70&#xD;
&#xD;
          2. Patients with solid tuomors at advanced stage must be histologically or cytologically&#xD;
             confirmed ,and be suitable for treating with Paclitaxel Liposome solo&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status (PS)is from 0 to 2&#xD;
&#xD;
          4. Patients who are expected to live at least 3 months&#xD;
&#xD;
          5. Laboratory tests before the study: white blood count (WBC)≥4,000/mm³,absolute&#xD;
             neutrophil count (ANC) ≥1,500/mm³, platelet count ≥100,000/mm³, hemoglobin≥9.0 g/dL,&#xD;
             aspartate aminotransferase AST (sGOT) and alanine aminotransferase ALT(sGPT)≤2.5 times&#xD;
             of normal value upper limit，serum creatinine≤1.0 time of normal value upper&#xD;
             limit，total bilirubin≤1.5 times of normal value upper limit&#xD;
&#xD;
          6. Not using chemotherapeutics (including test drug)before the study trial at least 4&#xD;
             weeks&#xD;
&#xD;
          7. No obvious functional disturbance diseases of internal organs&#xD;
&#xD;
          8. Complying with the study protocol&#xD;
&#xD;
          9. Sign informed consent&#xD;
&#xD;
         10. No Previous anaphylactic reaction to hormone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to any medication or foods; History of hypersensitivity reactions to the&#xD;
             conventional dosage form of paclitaxel or correlate excipients&#xD;
&#xD;
          2. Active uncontrolled central nervous system metastasis&#xD;
&#xD;
          3. Severe complications that obviously influence the compliance of patients&#xD;
&#xD;
          4. Grade ≥1 neuropathy using NCI CTCAE version 3.0 criteria&#xD;
&#xD;
          5. Taking other study medications or participating other clinical trial within 4w&#xD;
&#xD;
          6. Having radiation therapy or operation within 4w&#xD;
&#xD;
          7. Any non-remission toxicity ≥ CTC 1 in prior anticancer therapy(including radiation&#xD;
             therapy) (except alopecie and hemoglobin)&#xD;
&#xD;
          8. Pregnant or lactant women; fertile patients not using effective contraception during&#xD;
             study&#xD;
&#xD;
          9. No chief organ functional disturbance or diseases:&#xD;
&#xD;
               -  abnormal liver and renal functions&#xD;
&#xD;
               -  myocardial infarction&#xD;
&#xD;
               -  active heart disease&#xD;
&#xD;
               -  neuropathy or mental diseases including dementia or epilepsy&#xD;
&#xD;
               -  blind、deaf、dumb or extremity disability&#xD;
&#xD;
               -  known infection&#xD;
&#xD;
               -  active diffuse intravascular coagulation&#xD;
&#xD;
         10. Others whom researchers regard not eligible for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The ethics committee of Cancer Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>April 14, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>April 14, 2009</last_update_submitted>
  <last_update_submitted_qc>April 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jin Li, Dr.</name_title>
    <organization>Cancer Hospital of Fudan University</organization>
  </responsible_party>
  <keyword>Liposomal Paclitaxel</keyword>
  <keyword>Maximum tolerated dose</keyword>
  <keyword>Dose limiting toxicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

